Meningococcemia screening
Jump to navigation
Jump to search
|
Meningococcemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningococcemia screening On the Web |
|
American Roentgen Ray Society Images of Meningococcemia screening |
|
Risk calculators and risk factors for Meningococcemia screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Routine screening is not recommended for meningococcemia.
Screening
- Routine antimicrobial susceptibility testing of meningococcal isolates is not currently recommended.
- Surveillance of susceptibility patterns in populations should be conducted in order to monitor trends in N. meningitidis susceptibility.
- State and local health departments should notify the Centers for Disease Control and Prevention (CDC) if resistance to ciprofloxacin or other agents used for treatment or prophylaxis is detected.
- Passive and active surveillance systems are used to monitor meningococcal disease, which is a reportable disease in the United States. Through a national passive reporting system, state health departments collect and transmit weekly reports of cases to CDC through the National Electronic Telecommunications System for Surveillance (NETSS).
- The goals of meningococcal surveillance are:
- To detect outbreaks of meningococcal disease so that appropriate control measures can be promptly instituted, and
- To assess changes in the epidemiology of meningococcal disease over time to permit the most efficient allocation of resources and formulation of the most effective disease control and prevention policies.
- Meningococcal serogroup surveillance data are important to monitor the impact of quadrivalent meningococcal conjugate vaccine.
- Meningococcal serogroup data also help to determine the epidemiologic link between cases in cluster or outbreak situations.[1]